Repairing and regenerating damaged musculoskeletal tissues is one of the greatest challenges in regenerative medicine. Blood contains the essential ingredients to biologically engineer drug delivery devices that provide spatiotemporal control over the availability of a wide range of autologous agents, including small molecules, cytokines, and growth factors. This opinion article summarizes our current knowledge of blood-derived biological drug delivery therapies. The potential mechanisms that control protein release are discussed, along with the biological rationale and effects of their use in different relevant musculoskeletal tissues, including articular cartilage, bone, tendon, muscle, and nerve tissue injuries. Finally, we finally describe the current challenges facing the field and recent advances that should drive novel solutions for the musculoskeletal system.
Trends in Biotechnology – Elsevier
Published: Mar 1, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera